Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Didanosine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.61 |
| ▸ | LMNA | P02545 | 1/20 | 0.61 |
| ▸ | ALB | P02768 | 1/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.61 |
| ▸ | ABL1 | P00519 | 2/20 | 0.48 |
| ▸ | RIN1 | Q13671 | 2/20 | 0.48 |
| ▸ | ADA | P00813 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Didanosine SCHEMBL1769151 | 1.00 | ALDH1A1 (0.61) | ALDH1A1LMNAALBMAPK1ABL1 | |
| Didanosine SCHEMBL12150307 | 1.00 | ALDH1A1 (0.61) | ALDH1A1LMNAALBMAPK1ABL1 | |
| Didanosine SCHEMBL7910803 | 0.99 | ALDH1A1 (0.60) | ALDH1A1LMNAALBMAPK1ABL1 | |
| Didanosine SCHEMBL8709115 | 0.99 | ALDH1A1 (0.60) | ALDH1A1LMNAALBMAPK1ABL1 | |
| Didanosine SCHEMBL7910809 | 0.99 | ALDH1A1 (0.60) | ALDH1A1LMNAALBMAPK1ABL1 | |
| Didanosine SCHEMBL7907423 | 0.97 | ALDH1A1 (0.59) | ALDH1A1LMNAALBMAPK1ABL1 | |
| Didanosine SCHEMBL7907418 | 0.97 | ALDH1A1 (0.59) | ALDH1A1LMNAALBMAPK1ABL1 | |
| Didanosine SCHEMBL9223571 | 0.94 | ALDH1A1 (0.56) | ALDH1A1LMNAALBMAPK1ABL1 | |
| Didanosine SCHEMBL8025110 | 0.94 | ALDH1A1 (0.58) | ALDH1A1LMNAALBMAPK1ABL1 | |
| Didanosine SCHEMBL9594496 | 0.93 | ADA (0.58) | ALDH1A1LMNAALBMAPK1ADA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 11344 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260144879-A1 | ANTI-VIRAL AND HEPATIC-TARGETED DRUGS | AI-BIOPHARMA (FR) | 2026-05-28 | — | — | US | claimed |
| EP-4727950-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE IN THE TREATMENT OF MYCOBACTERIAL INFECTIONS | GlaxoSmithKline Intellectual Property Development Ltd (GB) | 2026-04-22 | — | — | EP | claimed |
| EP-3991729-B1 | USE OF AMLEXANOX IN PREPARING ANTI-HEPATITIS VIRUS DRUG | MARINE BIOMEDICAL RES INST QINGDAO CO LTD (CN) | 2026-03-25 | — | — | EP | claimed |
| EP-4698174-A1 | DOSING REGIMEN OF CAPSID INHIBITOR | GILEAD SCIENCES, INC. (US) | 2026-02-25 | — | — | EP | claimed |
| US-20250263678-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF RNA | REJUVENATION TECHNOLOGIES, INC. (US) | 2025-08-21 | — | — | US | claimed |
| CN-120078775-A | Capsid inhibitors for the treatment of HIV | 吉利德科学公司 | 2025-06-03 | — | — | CN | claimed |
| CN-120053445-A | Capsid inhibitors for the treatment of HIV | 吉利德科学公司 | 2025-05-30 | — | — | CN | claimed |
| CN-120053447-A | Capsid inhibitors for the treatment of HIV | 吉利德科学公司 | 2025-05-30 | — | — | CN | claimed |
| EP-4547335-A2 | ANTI-SARS-COV-2 ANTIGEN BINDING POLYPEPTIDES, POLYPEPTIDE COMPLEXES AND METHODS OF USE THEREOF | Modex Therapeutics, Inc. (US) | 2025-05-07 | — | — | EP | claimed |
| US-20250129084-A1 | Compounds | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2025-04-24 | — | — | US | claimed |
| WO-1989011274-A1 | CHEMOTHERAPEUTIC COMPOSITION FOR AIDS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY TH (US) | 1989-11-30 | — | — | WO | claimed |
| WO-1989011277-A2 | PORPHYRIN AND PHTHALOCYANINE ANTIVIRAL COMPOSITIONS | GEORGIA STATE UNIVERSITY FOUNDATION, INC. (US) | 1989-11-30 | — | — | WO | claimed |
| US-4861759-A | Antiviral compositions and methods | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1989-08-29 | — | — | US | claimed |
| US-4835104-A | Process for producing and purifying 2',3'-dideoxynucleosides, and process for producing 2',3'-dideoxy-2',3'-didehydronucleosides | AJINOMOTO CO., INC., PATENT & LICENSING DEPARTMENT (JP) | 1989-05-30 | — | — | US | claimed |
| EP-0312222-A1 | Treatment of diseases caused by viruses | Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo (JP) | 1989-04-19 | — | — | EP | claimed |
| EP-0270317-A2 | Pharmaceutical compositions for the treatment of diseases caused by viruses | Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo (JP) | 1988-06-08 | — | — | EP | claimed |
| US-4704357-A | TESTING DRUGS FOR EFFICARY AGAINST AIDS VIRUS | UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1987-11-03 | — | — | US | claimed |
| EP-0216510-A2 | Inhibition of in vitro infectivity and cytopathic effect of HTLV-III/LAV by 2'3'-dideoxyinosine, 2'3'-dideoxyguanosine, or 2'3'-dideoxyadenosine | THE UNITED STATES OF AMERICA as represented by the Secretary United States Department of Commerce (US) | 1987-04-01 | — | — | EP | claimed |
| WO-1987001284-A1 | INHIBITION OF IN VITRO INFECTIVITY AND CYTOPATHIC EFFECT OF HTLV-III/LAV BY 2',3'-DIDEOXYNOSINE, 2',3'-DIDEOXYGUANOSINE, OR 2',3'-DIDEOXYADENOSINE | UNITED STATES OF AMERICA, REPRESENTED BY THE UNITE (US) | 1987-03-12 | — | — | WO | claimed |
| EP-0206497-A2 | Therapeutic nucleosides and their preparation | THE WELLCOME FOUNDATION LIMITED (GB) | 1986-12-30 | — | — | EP | claimed |